Cargando…
The association between obesity and poor outcome after COVID-19 indicates a potential therapeutic role for montelukast
It is widely believed that infection with the SARS-CoV-2 virus triggers a disproportionate immune response which causes a devastating systemic injury, particularly in individuals with obesity, itself a chronic, multi-organ inflammatory disease. Immune cells accumulate in visceral adipose tissue and...
Autores principales: | Almerie, Muhammad Qutayba, Kerrigan, David Daniel |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Authors. Published by Elsevier Ltd.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7255216/ https://www.ncbi.nlm.nih.gov/pubmed/32492562 http://dx.doi.org/10.1016/j.mehy.2020.109883 |
Ejemplares similares
-
The Leukotriene Receptor Antagonist Montelukast as a Potential COVID-19 Therapeutic
por: Aigner, Ludwig, et al.
Publicado: (2020) -
Role of Montelukast in Asthma and Allergic rhinitis patients
por: Zuberi, Faisal Faiyaz, et al.
Publicado: (2020) -
Montelukast: The New Therapeutic Option for the Treatment of Epilepsy
por: Tesfaye, Bekalu Amare, et al.
Publicado: (2021) -
As a potential treatment of COVID-19: Montelukast
por: Fidan, Cihan, et al.
Publicado: (2020) -
Role of Montelukast in Improving Quality of Life in Patients with Persistent Asthma
por: Ikram, Ayesha, et al.
Publicado: (2019)